These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

137 related items for PubMed ID: 9100248

  • 1. Newer therapies for Parkinson's disease.
    Korczyn AD, Nisipeanu P.
    Neurol Neurochir Pol; 1996; 30 Suppl 2():105-11. PubMed ID: 9100248
    [No Abstract] [Full Text] [Related]

  • 2. [Use of dopamine agonists in the treatment of Parkinson's disease].
    Gekht AB.
    Zh Nevrol Psikhiatr Im S S Korsakova; 2002; 102(9):54-8. PubMed ID: 12378886
    [No Abstract] [Full Text] [Related]

  • 3. Second generation of dopamine agonists: pros and cons.
    Rabey JM.
    J Neural Transm Suppl; 1995; 45():213-24. PubMed ID: 8748628
    [Abstract] [Full Text] [Related]

  • 4. Combination of two different dopamine agonists in the management of Parkinson's disease.
    Stocchi F, Berardelli A, Vacca L, Thomas A, De Pandis MF, Modugno N, Valente M, Ruggieri S.
    Neurol Sci; 2002 Sep; 23 Suppl 2():S115-6. PubMed ID: 12548370
    [Abstract] [Full Text] [Related]

  • 5. Dopamine agonists as primary treatment in Parkinson's disease.
    Rinne UK.
    Adv Neurol; 1987 Sep; 45():519-23. PubMed ID: 3103394
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Neuroprotection in Parkinson's disease.
    Montastruc JL, Rascol O, Senard JM.
    Lancet; 1996 Jan 20; 347(8995):196. PubMed ID: 8544568
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Conversion from dopamine agonists to cabergoline: an open-label trial in 128 patients with advanced Parkinson disease.
    Linazasoro G, Spanish Dopamine Agonists Study Group.
    Clin Neuropharmacol; 2008 Jan 20; 31(1):19-24. PubMed ID: 18303487
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Dopamine agonists, Dopplers and doubt: cabergoline-associated cardiac valvulopathy.
    Pullan PT.
    Intern Med J; 2009 Apr 20; 39(4):213-5. PubMed ID: 19402858
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Update on dopamine agonists in Parkinson's disease: "beyond bromocriptine".
    Lang AE.
    Can J Neurol Sci; 1987 Aug 20; 14(3 Suppl):474-82. PubMed ID: 3315148
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. New dopamine agonists on the horizon.
    Heins JR.
    S D J Med; 1997 Jul 20; 50(7):239-40. PubMed ID: 9240032
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.